Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Havaintotutkimus avelumabin ja aksitinibin yhdistelmän tehokkuuden ja turvallisuuden arvioimiseksi osallistujilla, joilla on aRCC (AVION)

keskiviikko 20. toukokuuta 2026 päivittänyt: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Avelumabin (BAVENCIO®) + aksitinibin (INLYTA®) tehon ja turvallisuuden todellinen arviointi potilailla, joilla on aRCC useissa EU-maissa (AVION)

Tämän tutkimuksen päätarkoituksena on laajentaa tietoa Avelumabin suonensisäisen infuusion tehokkuudesta yhdessä aksitinibin kanssa ensilinjan hoitona potilailla, joilla on pitkälle edennyt munuaissolusyöpä (aRCC), turvallisuuden ja siedettävyyden lisäksi päivittäisissä rutiiniolosuhteissa. hoitokäytäntö.

Tutkimuksen yleiskatsaus

Tila

Valmis

Ehdot

Opintotyyppi

Havainnollistava

Ilmoittautuminen (Todellinen)

105

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

  • Belgia
      • Bonheiden, Belgia
        • Imelda Ziekenhuis
      • Brasschaat, Belgia
        • AZ Klina
      • Bruges, Belgia
        • AZ Sint-Jan
  • Kreikka
      • Athens, Kreikka
        • Gen. Hos. "Alexandra"
      • Athens, Kreikka
        • General Hospital of Athens G.Gennimatas
      • Athens, Kreikka
        • Henry Dunant Hospital Center
      • Athens, Kreikka
        • University Hospital of Athens Sotiria
      • Attiki, Kreikka
        • Attikon Hospital
      • Chaïdári, Kreikka
        • Attikon
      • Heraklion, Kreikka
        • General Hospital "Venizelio"
      • Ioannina, Kreikka
        • University Hospital of Ioannina
      • Kavala, Kreikka
        • Kavala General Hospital
      • Larissa, Kreikka
        • University Hospital of Larissa
      • Piraeus, Kreikka
        • Metaxa Hospital
      • Piraeus, Kreikka
        • Metropolitan Hospital Greece
      • Pátrai, Kreikka
        • General Hospital of Patras "o Agios Andreas"
      • Thessaloniki, Kreikka
        • Papageorgiou Hospital
      • Thessaloniki, Kreikka
        • Agios Loukas Hospital
      • Thessaloniki, Kreikka
        • Bioclinic (GRC)
      • Thessaloniki, Kreikka
        • Saint Luke Hospital
  • Saksa
      • Amberg, Saksa
        • Klinikum St. Marien Amberg
      • Aschaffenburg, Saksa
        • Klinikum Aschaffenburg Medizinische Klinik
      • Berlin, Saksa
        • Zentrum für urologische Onkologie
      • Biberach an der Riss, Saksa
        • Biberach
      • Bielefeld, Saksa
        • Evangelisches Klinikum Bethel
      • Bielefeld, Saksa
        • Evangelisches Krankenhaus Bielefeld
      • Braunschweig, Saksa
        • Urologie im Schlosscarree
      • Deggendorf, Saksa
        • Donauisar Klinikum Deggendorf
      • Dresden, Saksa
        • Urologische Gemeinschaftspraxis
      • Eisenach, Saksa
        • St. Georg Klinikum Eisenach gGmbH
      • Erlangen, Saksa
        • Universitätsklinikum Erlangen
      • Essen, Saksa
        • Universitaetsklinikum Essen Uroonkologie
      • Friedrichshafen, Saksa
        • Klinikum Friedrichshafen GmbH daVinci® -Zentrum Bodensee
      • Fürth, Saksa
        • Onkologische GP Dres. Wilke/Wagner/Petzoldt
      • Fürth, Saksa
        • Onkologische SP Praxis Fürth
      • Goslar, Saksa
        • MVZ Onkologische Kooperation Harz GbR
      • Halberstadt, Saksa
        • Praxis Dr. Maas
      • Hamburg, Saksa
        • Universitätsklinikum Hamburg-Eppendorf
      • Hanover, Saksa
        • Medizinische Hochschule Hannover
      • Hanover, Saksa
        • Vinzenzkrankenhaus Hannover
      • Heinsberg, Saksa
        • Praxis Kretz
      • Jena, Saksa
        • Universitätskinderklinik Jena
      • L.-Eisleben, Saksa
        • Urologische Praxis Dr. Ralf Eckert
      • Luckenwalde, Saksa
        • Urologische Praxis Dipl.-Med. Susanne Kloß
      • Lübeck, Saksa
        • Universitatsklinik Schleswig-Holstein
      • Magdeburg, Saksa
        • Schwerpunktpraxis für Hämatologie und Onkologie
      • Minden, Saksa
        • Johannes Wesling Klinikum Minden der Mühlenkreiskliniken (AöR)
      • Münster, Saksa
        • University of Munster
      • Münster, Saksa
        • Uniklinikum Münster
      • Osnabrück, Saksa
        • Marienhospital Osnabrück - Standort Natruper Holz
      • Osnabrück, Saksa
        • Paracelsus Klinik Osnabrück
      • Osnabrück, Saksa
        • Klinikum Osnabrück GmbH
      • Ostfildren, Saksa
        • medius Klinik Ostfildern-Ruit
      • Rostock, Saksa
        • Wissenschaftskontor Nord GmbH & Co. KG
      • Rüsselsheim am Main, Saksa
        • GPR Klinikum Rüsselsheimg GmbH
      • Sigmaringen, Saksa
        • SRH Kliniken Landkreis Sigmaringen (DEU)
      • Stolberg, Saksa
        • Hämatologie und Onkologie Stolberg
      • Troisdorf, Saksa
        • Praxis Troisdorf
      • Westerstede, Saksa
        • Medizinische Studiengesellschaft Nord-West GmbH
      • Wetzlar, Saksa
        • Lahn Dill Kliniken GmbH
  • Venäjä
      • Irkutsk, Venäjä
        • Regional Oncology Dispensary - Irkutsk

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Näytteenottomenetelmä

Ei-todennäköisyysnäyte

Tutkimusväestö

Osallistujia, joilla on vahvistettu pitkälle edennyt RCC-diagnoosi, tarkkaillaan tässä tutkimuksessa.

Kuvaus

Sisällyttämiskriteerit:

  • Osallistujat, joiden ECOG:n (Eastern Cooperative Oncology Group) suorituskyky on 0, 1 tai 2
  • Osallistujat, joilla on histologisesti vahvistettu RCC-diagnoosi mistä tahansa histologisesta alkuperästä
  • Osallistujat, joilla on paikallisesti edennyt/metastaattinen sairaus (eli [eli] äskettäin diagnosoitu vaiheen 4 RCC / American Joint Committee on Cancer) tai joilla on uusiutuva sairaus
  • Osallistujat ovat saaneet 1 tai 2 sykliä Avelumab plus Axitinib -hoitoa ensilinjan hoitona hyväksytyn valmisteyhteenvedon (SmPC) mukaisesti.
  • Osallistujat, jotka haluavat allekirjoittaa kirjallisen tietoisen suostumuslomakkeen (ICF) osallistuakseen tähän tutkimukseen

Poissulkemiskriteerit:

  • Osallistujat, joilla on avelumabin tai aksitinibin käytön vasta-aiheet hyväksytyn valmisteyhteenvedon mukaan
  • Osallistujat, jotka ovat osallistuneet lääkkeen tai laitteen interventiotutkimukseen 28 päivän aikana ennen Avelumab plus Axitinib -hoidon aloittamista

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

Kohortit ja interventiot

Ryhmä/Kohortti
Avelumabi + aksitinibi
Tässä tutkimuksessa ei tehdä tutkimuskohtaisia ​​interventioita. Osallistujia, joilla on pitkälle edennyt RCC ja jotka saavat 800 milligrammaa (mg) Avelumabia suonensisäisesti joka toinen viikko yhdessä 5 mg aksitinibin kanssa suun kautta kahdesti päivässä ensilinjan hoidon myyntilupaehtojen mukaisesti nykyisen kliinisen käytännön mukaisesti, tarkkaillaan. 24 kuukauden ajan tässä tutkimuksessa.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Overall Survival Rate
Aikaikkuna: At 12 months after index date (baseline visit as reported in the electronic case report form [eCRF])
Overall survival rate was defined as the percentage of participants who are alive at 12 months after the index date. Percentage of participants alive at the time of outcome assessment (12 months) were calculated as per the Kaplan-Meier (KM) approach. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
At 12 months after index date (baseline visit as reported in the electronic case report form [eCRF])

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Overall Survival Rate
Aikaikkuna: At 24 months after index date (baseline visit as reported in the eCRF)
Overall survival rate was defined as the percentage of participants who are alive at 24 months after the index date. Percentage of participants alive at the time of outcome assessment (24 months) were calculated as per the Kaplan-Meier (KM) approach. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
At 24 months after index date (baseline visit as reported in the eCRF)
Duration of Overall Survival
Aikaikkuna: From the index date (baseline visit as reported in the eCRF) to the date of death from any cause, (assessed up to 24 months after index date)
Duration of overall survival is defined as the time from index date to the date of death due to any cause. The overall survival was analyzed by using the Kaplan-Meier method. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
From the index date (baseline visit as reported in the eCRF) to the date of death from any cause, (assessed up to 24 months after index date)
Objective Response Rate (ORR) Assessed by Investigator up to 24 Months After the Index Date
Aikaikkuna: up to 24 months after the index date (baseline visit as reported in the eCRF)
Objective response rate was defined as percentage of participants with either a confirmed complete response (CR) or partial response (PR) as best overall response up to 24 months after the index date. CR: Disappearance of all target and non-target lesions. PR: At least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum of their diameters, and no unequivocal progression of non-target lesions. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
up to 24 months after the index date (baseline visit as reported in the eCRF)
Disease Control Rate (DCR) Assessed by Investigator up to 24 Months After the Index Date
Aikaikkuna: up to 24 months after the index date (baseline visit as reported in the eCRF)
Disease control rate is defined as the percentage of participants with objective response (complete response [CR] or partial response [PR] or stable disease [SD]) as best overall response up to 24 months after the index date. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SLD while on study. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
up to 24 months after the index date (baseline visit as reported in the eCRF)
Duration of Response (DoR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Aikaikkuna: up to 24 months after the index date (baseline visit as reported in the eCRF)
DoR was defined for participants with objective response, as the time from first documentation of objective response (Complete Response [CR] or Partial Response [PR]) to the date of first documentation of progression disease (PD) or death due to any cause, whichever occurred first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
up to 24 months after the index date (baseline visit as reported in the eCRF)
Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1 Assessed by Investigator
Aikaikkuna: From the index date (baseline visit as reported in the eCRF) to the date of disease progression or death from any cause, whichever occurred first (assessed up to 24 months after index date)
PFS time was defined as the time from index date to the date of the first documentation of objective progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST version 1.1, PD was defined as at least a 20 percent (%) increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeter (mm). The appearance of one or more new lesions was also considered PD. The tumor response was determined according to RECIST version 1.1 and assessed by the investigator. PFS was calculated based on KM method. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
From the index date (baseline visit as reported in the eCRF) to the date of disease progression or death from any cause, whichever occurred first (assessed up to 24 months after index date)
Progression-free Survival 2 (PFS2) According to RECIST Version 1.1 Assessed by Investigator
Aikaikkuna: From the index date (baseline visit as reported in the eCRF) to the date of disease progression on second-line treatment or death from any cause, whichever occurred first (assessed up to 24 months after index date)
PFS2 was defined as time interval from the index date to the date of disease progression on second-line treatment or death from any cause, whichever occurred first. Per RECIST version 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. The tumor response will be determined according to RECIST version 1.1 and assessed by the investigator. PFS2 was calculated based on Kaplan Meier method. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
From the index date (baseline visit as reported in the eCRF) to the date of disease progression on second-line treatment or death from any cause, whichever occurred first (assessed up to 24 months after index date)
Change From Baseline in National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index 19 (NCCN-FACT FKSI-19) Total Score
Aikaikkuna: Index date (baseline visit as reported in the eCRF), at 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72, 78, 84, 90, 96, 102 and 104 weeks
NCCN-FACT FKSI-19, a validated, disease-specific questionnaire for RCC. It includes 19 items across four domains, Disease-Related Symptoms-Physical (DRS-P), Disease-Related Symptoms-Emotional (DRS-E), Treatment Side Effects (TSE), and Functional Wellbeing (FWB), based on symptoms experienced over past 7 days. Responses were recorded on 5-point Likert scale (0 = not at all to 4 = very much), yielding a total score from 0 to 76, higher scores reflecting better quality of life. A negative mean change in score indicated worsening condition. Domain score ranges and directionality: DRS-P: 0-48, higher scores = fewer physical symptoms; DRS-E: 0-4, higher = fewer emotional symptoms; TSE: 0-12, higher = more severe side effects; FWB: 0-12, higher = better functional wellbeing. As per NCCN-FACT FKSI-19 scoring guidelines, the total Health-related quality of life (HRQoL) score (range 0-76) was calculated as sum of single items scores multiplied by 19 and divided by the number of items completed.
Index date (baseline visit as reported in the eCRF), at 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72, 78, 84, 90, 96, 102 and 104 weeks
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Related TEAEs, TEAEs Leading to Permanent Treatment Discontinuation and TEAEs Leading to Death According to Medical Dictionary for Regulatory Activities (MedDRA)
Aikaikkuna: From the index date (baseline visit as reported in the eCRF) up to 90 days post discontinuation of avelumab plus axitinib or completion of the 24 months (i.e., end of the study) follow-up from the index date, whichever occurred first
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether considered related to the study intervention or not. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as events with onset date or worsening during the on-treatment period. TEAEs included both serious and non-serious TEAEs. Treatment-related TEAEs is defined as reasonably related to the study intervention. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
From the index date (baseline visit as reported in the eCRF) up to 90 days post discontinuation of avelumab plus axitinib or completion of the 24 months (i.e., end of the study) follow-up from the index date, whichever occurred first
Number of Participants With Adverse Events Based on Severity According to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0
Aikaikkuna: From the index date (baseline visit as reported in the eCRF) up to 90 days post discontinuation of avelumab plus axitinib or completion of the 24 months (i.e., end of the study) follow-up from the index date, whichever occurred first
Severity of TEAEs were evaluated using the NCI-CTCAE version 5.0. The grade are as follows: grade 1 : mild grade 2 : moderate grade 3 : severe or medically significant but not immediately life-threatening grade 4 : life threatening or disabling grade 5 : death related to AE. Number of participants with TEAEs grade greater than or equal to (>=) 3 were reported. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
From the index date (baseline visit as reported in the eCRF) up to 90 days post discontinuation of avelumab plus axitinib or completion of the 24 months (i.e., end of the study) follow-up from the index date, whichever occurred first
Time to Therapy Discontinuation Due to AE Greater Than or Equal to (>=) Grade-3
Aikaikkuna: From the index date (baseline visit as reported in the eCRF) up to 24 months
Time to therapy discontinuation due to AE >= grade 3 was reported. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
From the index date (baseline visit as reported in the eCRF) up to 24 months
Duration of Avelumab Plus Axitinib Therapy Among Participants Who Discontinued the Axitinib Due to All-Cause AEs >= Grade 3
Aikaikkuna: Time from first dose of study drug up to 24 months
The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC. Duration of Avelumab plus Axitinib therapy (days) = (Date of discontinuation of Axitinib - Date of index date + 1). Duration of avelumab plus axitinib therapy among participants who discontinued the Axitinib due to all-cause AEs >= grade 3 was reported.
Time from first dose of study drug up to 24 months
Time to Onset of Treatment - Emergent Adverse Events (TEAEs)
Aikaikkuna: From index date (baseline visit as reported in the eCRF) up to 24 months
Time to onset of TEAE = Start date TEAE - Index date. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
From index date (baseline visit as reported in the eCRF) up to 24 months
Duration of Treatment-Emergent Adverse Events (TEAEs)
Aikaikkuna: From index date (baseline visit as reported in the eCRF) up to 24 months
Duration of TEAE = (Stop date of TEAE - Start date of TEAE + 1) divided by 7. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
From index date (baseline visit as reported in the eCRF) up to 24 months
Percentage of Participants With Therapy Modifications Due to Adverse Event Related to Avelumab Plus Axitinib Therapy
Aikaikkuna: From index date (baseline visit as reported in the eCRF) up to 24 months
Percentage of participants with therapy modifications due to AE related to avelumab plus axitinib therapy were reported. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
From index date (baseline visit as reported in the eCRF) up to 24 months
Number of Participants With Different Types of Medical Intervention or Medications Used for the Management of TEAEs Related to Avelumab Plus Axitinib Therapy
Aikaikkuna: From index date (baseline visit as reported in the eCRF) up to 24 months after the index date
Number of participants with different types of medical intervention or medications used for the management of TEAE related to avelumab plus axitinib therapy (e.g., use of corticosteroids, antihypertensive therapy, treatment for thyroid dysfunction, measures to decrease hemoglobin, and hematocrit) was reported. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
From index date (baseline visit as reported in the eCRF) up to 24 months after the index date
Percentage of Participants Receiving Later-line Therapy
Aikaikkuna: From index date (baseline visit as reported in the eCRF) up to 24 months
Percentage of participants receiving later-line therapy were reported. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
From index date (baseline visit as reported in the eCRF) up to 24 months
Time to Second-line Therapy Initiation
Aikaikkuna: Time from Avelumab plus Axitinib therapy discontinuation to the initiation of second-line therapy, assessed up to 24 months
Time to second line treatment was calculated as: (second line treatment start date - last dose of Avelumab plus Axitinib + 1)/30.4375.
Time from Avelumab plus Axitinib therapy discontinuation to the initiation of second-line therapy, assessed up to 24 months
Number of Participants With Patient-reported Potential Signs and Symptoms of Immune-related AEs
Aikaikkuna: From index date (baseline visit as reported in the eCRF) up to 24 months
Number of participants with patient-reported potential signs and symptoms of immune-related AEs were reported. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
From index date (baseline visit as reported in the eCRF) up to 24 months

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Yhteistyökumppanit

Merck Healthcare Germany GmbH, an affiliate of Merck KGaA, Darmstadt, Germany

Tutkijat

  • Opintojohtaja: Medical Responsible, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Hyödyllisiä linkkejä

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Maanantai 9. elokuuta 2021

Ensisijainen valmistuminen (Todellinen)

Torstai 8. elokuuta 2024

Opintojen valmistuminen (Todellinen)

Keskiviikko 30. huhtikuuta 2025

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Keskiviikko 23. kesäkuuta 2021

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Keskiviikko 23. kesäkuuta 2021

Ensimmäinen Lähetetty (Todellinen)

Maanantai 28. kesäkuuta 2021

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Tiistai 16. kesäkuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Keskiviikko 20. toukokuuta 2026

Viimeksi vahvistettu

Perjantai 1. toukokuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Avainsanat

Muita asiaankuuluvia MeSH-ehtoja

Muut tutkimustunnusnumerot

  • MS100070_0110

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa